Clinical features of biochemical cholestasis in patients with recurrent hepatitis C after living-donor liver transplantation

Journal of Viral Hepatitis

Volumn 17, Issue 7, 2010, Pages 481-487

  Ueda, Y ^a   Takada, Y ^a   Marusawa, H ^a   Haga, H ^a   Sato, T ^b   Tanaka, Y ^a   Egawa, H ^a   Uemoto, S ^a   Chiba, T ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

Author keywords

Cholestasis; Hepatitis C; Living donor liver transplantation; Th1

Indexed keywords

CYCLOSPORIN; INTERFERON; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2B; RIBAVIRIN; STEROID; TACROLIMUS; VIRUS RNA; ALKALINE PHOSPHATASE; GAMMA GLUTAMYLTRANSFERASE;

ARTICLE; CHOLESTASIS; CLINICAL FEATURE; DISEASE COURSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RECURRENT INFECTION; SURVIVAL RATE; TREATMENT RESPONSE; VIRUS HEPATITIS; BLOOD; COMPLICATION; CYTOCHEMISTRY; IMMUNOLOGY; LIVER; LIVER CIRRHOSIS; PATHOLOGY; RECURRENT DISEASE; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

ALKALINE PHOSPHATASE; CHOLESTASIS; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS C; HISTOCYTOCHEMISTRY; HUMANS; INTERFERONS; LIVER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONORS; RECURRENCE; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 77953557907     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01207.x     Document Type: Article

References (31)

1. Berenguer M, Prieto M, San Juan F et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002 36 (1) 202-210.
2. Feray C, Caccamo L, Alexander GJ et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999 117 (3) 619-625.
3. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002 122 (4) 889-896.
4. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003 9 (11) S28-S34.
5. Prieto M, Berenguer M, Rayon JM et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999 29 (1) 250-256.
6. Sanchez-Fueyo A, Restrepo JC, Quinto L et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002 73 (1) 56-63.
7. Velidedeoglu E, Mange KC, Frank A et al. Factors differentially correlated with the outcome of liver transplantation in hcv+ and HCV- recipients. Transplantation 2004 77 (12) 1834-1842.
8. Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000 32 (4) 673-684.
9. Kuo A, Terrault NA. Management of hepatitis C in liver transplant recipients. Am J Transplant 2006 6 (3) 449-458.
10. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003 9 (11) S1-S9.
11. Iacob S, Cicinnati VR, Hilgard P et al. Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation. Transplantation 2007 84 (1) 56-63.
12. Cotler SJ, Taylor SL, Gretch DR et al. Hyperbilirubinemia and cholestatic liver injury in hepatitis C-infected liver transplant recipients. Am J Gastroenterol 2000 95 (3) 753-759.
13. Dickson RC, Caldwell SH, Ishitani MB et al. Clinical and histologic patterns of early graft failure due to recurrnet hepatitis C in four patients after liver transplantation. Transplantation 1996 61 (5) 701-705.
14. Schluger LK, Sheiner PA, Thung SN et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996 23 (5) 971-976.
15. Ong JP, Younossi ZM, Gramlich T et al. Interferon alpha 2B and ribavirin in severe recurrent cholestatic hepatitis C. Transplantation 2001 71 (10) 1486-1487.
16. Cavicchi M, Beau P, Crenn P, Degott C, Messing B. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med 2000 132 (7) 525-532.
17. Lloyd DA, Zabron AA, Gabe SM. Chronic biochemical cholestasis in patients receiving home parenteral nutrition: prevalence and predisposing factors. Aliment Pharmacol Ther 2008 27 (7) 552-560.
18. Kumar KS, Saboorian MH, Lee WM. Cholestatic presentation of chronic hepatitis C: a clinical and histological study with a review of the literature. Dig Dis Sci 2001 46 (10) 2066-2073.
19. Takada Y, Haga H, Ito T et al. Clinical outcomes of living donor liver transplantation for hepatitis C virus (HCV)-positive patients. Transplantation 2006 81 (3) 350-354.
20. Ueda Y, Takada Y, Haga H et al. Limited benefit of biochemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver transplantation. Transplantation 2008 85 (6) 855-862.
21. Ohno O, Mizokami M, Wu RR et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997 35 (1) 201-207.
22. Morinobu A, Kumagai S. [Cytokine measurement at a single-cell level to analyze human Th1 and Th2 cells]. Rinsho Byori. 1998 46 (9) 908-914.
23. Schauer U, Jung T, Krug N, Frew A. Measurement of intracellular cytokines. Immunol Today 1996 17 (7) 305-306.
24. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996 24 (2) 289-293.
25. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997 349 (9055) 825-832.
26. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999 30 (3) 595-601.
27. Diepolder HM, Zachoval R, Hoffmann RM, Jung MC, Gerlach T, Pape GR. The role of hepatitis C virus specific CD4 + T lymphocytes in acute and chronic hepatitis C. J Mol Med 1996 74 (10) 583-588.
28. Gerlach JT, Diepolder HM, Jung MC et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999 117 (4) 933-941.
29. Kamal SM, Rasenack JW, Bianchi L et al. Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response. Gastroenterology 2001 121 (3) 646-656.
30. Sarih M, Bouchrit N, Benslimane A. Different cytokine profiles of peripheral blood mononuclear cells from patients with persistent and self-limited hepatitis C virus infection. Immunol Lett 2000 74 (2) 117-120.
31. Sobue S, Nomura T, Ishikawa T et al. Th1/Th2 cytokine profiles and their relationship to clinical features in patients with chronic hepatitis C virus infection. J Gastroenterol 2001 36 (8) 544-551.